Does brain insulin resistance reduce neuronal glucose use and promote amyloid-beta accumulation and abnormal tau phosphorylation?

Brain insulin resistance is a credible contributor to Alzheimer-related metabolic and protein-pathology changes, but the overall claim is better supported mechanistically and in experimental models than as a directly demonstrated causal pathway in humans.

Clinical and translational evidence

• Human FDG-PET literature consistently links insulin resistance or impaired glycemic status with lower cerebral glucose metabolism, including in Alzheimer-vulnerable regions. A meta-analysis of 31 studies found lower fasting metabolism in insulin-resistant groups (Hedges’ g −0.47, 95% CI −0.73 to −0.22); 22 of 23 studies in another review reported an adverse association. FDG-PET, however, reflects regional metabolism across cell types rather than neuronal glucose uptake specifically.
• Amyloid evidence is suggestive: in a 60-person Finnish cohort, midlife peripheral insulin resistance predicted amyloid-PET burden about 15 years later; positivity was 60% with insulin resistance versus 33.3% without. This remains an indirect measure of brain insulin responsiveness.
• Human tau findings are inconsistent. Associations of peripheral HOMA-IR with CSF p-tau181 differed by APOE ε4 status, while other studies found no association with p-tau181 or entorhinal tau PET.

Mechanistic evidence

• Impaired brain insulin-receptor/IRS signaling can reduce PI3K–AKT activity and AS160-dependent GLUT4 trafficking, providing a plausible route to diminished glucose uptake in insulin-responsive neurons.
• In diabetic mice and insulin-resistant rats, reduced AKT signaling decreases inhibitory phosphorylation—and therefore restraint—of GSK3β. Increased GSK3β activity, together with lower PP2A-mediated tau dephosphorylation, is linked to increased tau phosphorylation; insulin partly reversed these changes in some models.
• Alzheimer-model mice exposed to high-fat or Western diets showed impaired insulin signaling, altered APP processing, impaired extracellular amyloid-beta clearance, and greater amyloid pathology, although inflammatory and systemic metabolic effects co-occurred.

Bottom line

• Brain insulin resistance plausibly contributes to cerebral hypometabolism and amyloid-beta accumulation and has moderate experimental support as a driver of abnormal tau phosphorylation. In humans, however, available evidence is mainly associative and commonly relies on peripheral insulin-resistance measures rather than direct tests of central insulin signaling.